An update on mortality among workers at a 1,3-butadiene facility--preliminary results. by Divine, B J
Environmental Health Perspectives
Vol. 86, pp. 119-128, 1990
An Update on Mortality among Workers
at a 1,3-Butadiene Facility Preliminary
Results
by Barbara J. Divine*
This is a cohort study of 2582 male workers employed at least 6 months between 1943 and 1979 at a
1,3-butadiene manufacturing facility. An earlier report on mortality through 1979 found a statistically
significant deficit forallcausesofdeathandlowerthanexpectedmortalityfor mostofthe leadingcauses of
death. However, there was astatistically significant excessofdeaths from lymphosarcoma. This report is a
preliminary update ofcohort information through 1985 and also a reanalysis of mortality. The all-causes
standardized mortality ratio is 84 and that for all cancers is 80. These are statistically significant deficits;
significant deficits were also seenforall cancerofthedigestive system andall external causesofdeath. One
additional death from lymphosarcoma was observed during the extended follow-up period giving a statisti-
cally significant standardized mortality ratio (SMR) of 229. The increase was concentrated in those
employed less than 10 years and in those first employed before 1946. No increase was seen overall for
leukemia (SMR = 102).
Introduction
This study reports on updated cause-specific mor-
talityin acohortofworkersemployed at a1,3-butadiene
productionplant. The plant wasbuiltduringWorld War
II in Port Neches, TX, to supply 1,3-butadiene to two
adjacent rubber manufacturing facilities. This cohort
was the subject ofan earlier report (1) that covered the
period from the beginning of plant operation through
1979. The cohort consisted of all males who were em-
ployed at the plant for at least 6 months between the
time the plant began operation in 1943 and the end of
1979.
The earlier report found a statistically significant
deficit for all causes of death and lower than expected
mortality for almost all the leading causes ofdeath. The
only significant excess cause ofdeath seen was for lym-
phosarcoma and reticulum cell sarcoma. The cohort was
divided into four exposure groups (routine, nonroutine,
low, andunknown) andmortalitywas examined foreach
ofthegroups. Thestandardizedmortalityratios(SMRs)
for non-Hodgkin's lymphomas (International Classi-
fication of Diseases codes 200, 202, 203, and 208) were
elevated in all three known exposure groups. Direct
comparisons between the low exposure group and each
of the exposure groups for this cause of death were
inconsistent. Because of the continuing interest in de-
terminingwhether1,3-butadiene is ahumancarcinogen,
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information on the original cohort was updated through
1985.
Methods
The studypopulation is the same as that inthe earlier
report (1). The data were obtained from the previous
investigators and merged with company computerized
personnel files. Company data were used to update
information onthose persons stillemployed orknown to
be deceased. Dates of termination were obtained for
those who left after the previous study end date. Fur-
theredits were done, and two duplicaterecords andtwo
females were removed from the cohort.
Information was obtained from the Social Security
Administration (SSA) for those whose vital status was
unknown. This included all persons not known to be
currently working for the company or those noted as
deceased but for whom a death certificate was not lo-
cated. SSA datawere completethrough 1985although a
number ofdeaths in 1986 and 1987 were also identified.
Death certificates were requested from the states iden-
tified by SSA as most likely to have the information. At
the time of this report, death certificates had been
received from Texas, Louisiana, Ohio, and Mississippi.
Alldeathcertificates were codedforunderlyingcause of
death by a trained nosologist according to the Eight
Revision rules ofthe International Classification ofDis-
eases (ICD). Information on those whose vital status
wasunknownafterthe SSAsearchwassubmitted totheB. J. DIVINE
National Death Index (NDI). The NDI records were
searched for possible matches for deaths from 1979
through 1986.
The qualitative exposure classification scale de-
veloped for the previous report (1) was again used.
Therewerefourexposure groups: lowexposure, routine
exposure, nonroutine exposure, andunknownexposure.
Eachpersonwasassignedtoanexposuregroupbasedon
his department code. Although no industrial hygiene
sampling data are available for most of the period
covered bythe study, areview ofcurrent samplingdata
results supports the groupings.
Analysis ofmortality was performed using Monson's
computer program (2) to compare the observed and
expected number of deaths with the U.S. white male
population as the comparison group. White male rates
were used because ofuncertainties about the validity of
the race information inthe company files and because of
the small number of blacks who worked at the plant.
Person-years were accrued beginning when the person
metthe cohort eligibility criteria of6months ofemploy-
ment. Those persons with vital status unknown were
assumed to be lost to study on the date last observed.
Those persons who were alive as of the earlier study
end-date of12/31/79and forwhomthe NDI could find no
match were assumed to be alive. Persons known to be
deceased but for whom no death certificate could be
located were counted in the all-causes mortality but not
in the cause-specific mortality results.
It should be noted that while the previous report (1)
grouped all the non-Hodgkin's lymphomas together in
the tables (ICD codes 200, 202, 203, and 208), for this
report lymphosarcoma (ICD code 200) and cancers of
otherlymphatictissue (ICD codes202, 203, and208) are
reported separately.
Results
The final cohort consisted of 2582 men who had
worked for at least 6 months prior to the end of 1979.
Table 1 showsthedemographicandothercharacteristics
of the total cohort and of the four exposure cohorts
described above. There were 74,219 person-years of
follow-up, and the mean duration of survival was 28.7
years. There were826deathsknowntohaveoccurredin
the cohort through 1985, and death certificates were
obtained for all but 49 (6%) of them. There were 1708
persons still alive at the end ofthe study (66%) and 48
(1.9%) lost to follow-up.
Table 2 shows the SMRs for selected causes ofdeath
forthe total cohort and forthose employed greaterthan
5, 10, and 20 years. The SMR for all causes ofdeath for
the total cohort is significantly low at 84, as well as the
all-cancer SMR at 80. Deficits are again seen for almost
alltheleadingcausesofdeath. Thereisanelevated SMR
of 130 for lymphatic and hematopoietic cancer, which is
almostentirelyduetothesignificantlyincreasedSMRof
229 for lymphosarcoma and reticulosarcoma. The in-
crease for lymphosarcoma is seen primarily in those
employed fewer than 10 years. The only cause ofdeath
that increases as years ofemployment increases is can-
cer of the kidney, but both the observed and expected
Table 1. Demographic, employment, and other characteristics of the study population and exposure cohorts.
Cohort
Number of persons
Percent oftotal
Mean age of entry, years
Mean year of entry
Number hired between 1940-45
Percent of cohort
Mean years of employment
Number oflost to follow-up
Percent of each cohort
Number of person-years
Number of deaths
Percent ofdeaths in each cohort
Numberwithoutdeathcertificates
Percent of deaths
Mean age at death, years
Mean year of death
Lowexposure
I
433
(16.9%)
30.7
1954
165
(38%)
12.4
6
(1.4%)
11851.7
131
(30.0%)
11
(8.4%)
64.1
1973
Routine exposure
II
705
(27.3%)
27.5
1952
216
(31%)
12.4
6
(0.9%)
21423.1
163
(23.1%)
9
(5.5%)
59.2
1973
Nonroutineexposure
III
993
(38.5%)
32.5
1951
462
(47%)
11.6
26
(2.6%)
27433.8
361
(36.4%)
24
(6.7%)
64.2
1970
Unknown exposure
IV
451
(17.5%)
32.0
1949
223
(49%)
14.3
10
(2.2%)
13512.8
171
(37.9%)
5
(2.9%)
65.3
1971
27.4 30.4 27.1
Total
2582
(100%)
30.7
1952
1066
(41%)
12.4
48
(1.9%)
74218.8
826
(32.0%)
49
(6.0%)
63.4
1971
120
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riUPDATED MORTALITY AMONG BUTADIENE WORKERS
numbersofdeathsaresmallandtheconfidenceintervals
wide. One cause ofdeaththat issignificantly elevatedin
this update, as compared to the previous report, is
ill-defined symptoms and senility. (SMR = 200).
Table 3 shows the SMRs for selected causes ofdeath
for those first employed during World War II versus
those who were first employed after the war. The all-
causes SMR is similar for the two groups. The SMR is
increased for lymphohematopoietic cancer for both sub-
cohorts. Almost all the excess for those first employed
during the war is due to the significantly elevated SMR
for lymphosarcoma (SMR = 269). For those first em-
ployed after the war, elevated SMRs are seen for lym-
phosarcoma, Hodgkin's disease, and cancer of other
lymphatic tissue. None of these is statistically signifi-
cant, and the numbers of observed deaths are small.
Cancers of the large intestine and the pancreas are
nonsignificantly elevated for those first employed post-
war, whereasdeficitswere seenforthosefirstemployed
during the war. There is a slight elevation for leukemia
(SMR = 112)inthosefirstemployedduringthewar, but
it is based on less than one death.
Table 4 shows the SMRs for selected causes ofdeath
for each ofthe exposure groups for all in the subgroup
and for those employed 10 years or more in the group.
All groups except the unknown exposure group show
elevated SMRs for lymphohematopoietic cancer for
those everinthegroup. Forthelowexposuregroup, the
excess is due to elevated SMRs for lymphosarcoma and
Hodgkin's disease; both of these are based on two or
fewer observed deaths. The overall excess disappears
when the analysis is restricted to those employed 10
years or more. The routine exposure group has a statis-
tically significant excess of lymphosarcoma (SMR =
561), which accounts for most ofthe lymphohematopoi-
etic excess. All ofthe lymphosarcomas occurred in per-
sons employed fewer than 10 years. Cancer ofboth the
largeintestineandkidneyincreased fromthegroupever
employed to those employed 10 years or more.
Most ofthe excess inlymphohematopoietic cancer for
the nonroutine group is due to a nonsignificant increase
in leukemia (SMR = 185), which is limited to those
employed less than 10 years. Only a slight increase is
seen for this group for lymphosarcoma (SMR = 126).
Cancer ofthe prostate has a nonsignificant increase for
thoseemployed more than 10 years (SMR = 146), while
there is a deficit for the group overall. There is a non-
significant elevationforstrokeforthegroupoverall, but
this disappears when the group is restricted to those
employed morethan 10years. Cancerofthebrainshows
anelevated SMR(283) fortheunknownexposure group,
which increases for those employed more than 10 years
(SMR = 415). These SMRs are based on three or fewer
observed deaths, however. Both nonmalignant respi-
ratory disease and cirrhosis of the liver show non-
significantly elevated SMRs for the group employed 10
years or more, as compared to those ever in the group,
but neither increase is statistically significant. The in-
crease in respiratory disease is primarily due to an
increase in deaths from pneumonia (SMR = 232).
Thenumberofobservedandexpecteddeathsbyyears
workedandlatencyforallmalesforalldeaths, allcancer
deaths, all hemotopoietic deaths, lymphosarcoma, and
leukemia are shown in Table 5. Forall deaths the SMRs
are essentially unchanged as either latency or duration
increases. Similarly, nopatternwithlatencyorduration
is seen for all cancer deaths. For all hematopoietic
deaths, the largest elevation is seen for those with
latency and length ofemployment fewer than 10 years.
The SMRs actually decrease with increasing employ-
ment. Forlymphosarcoma, againthelargestelevationis
forthosewiththeshortestemploymentandlatency. The
SMRs forleukemiaincrease with increasinglatencybut
decrease with increasing length of employment.
Tables6through9showthe sameinformationforeach
ofthe four exposure groups. No overall pattern is seen
forthelow-exposuregroupotherthanthattheSMRsfor
all cancers and for all hematopoietic cancer tend to
decrease with increasing lengths of employment. For
the routine exposure group, again no pattern is seen.
Thebiggestexcessisseenforlymphosarcoma; alldeaths
occurred in those employed fewer than 10 years; two
were in those with fewer than 10 years latency, one in
those with 20 to 29 latency, and two in those with 30
years ormore oflatency. The mostinterestingresultfor
the nonroutine exposure group is for leukemia. Five of
the six deaths occurredinthose employedfewerthan 10
years, and all had at least 10 years oflatency although
the deaths were spread out among the other latency
categories. No pattern was seen for the unknown ex-
posure group.
Discussion
The overall pattern ofresults forthis update is essen-
tially unchanged from the earlier report on this cohort
(1). Therewasanoverallreductioninexpectedmortality
(SMR = 84) when compared with the U.S. white male
population, whichagainwasprimarilyduetoareduction
indeathsbecause ofarteriosclerotic heartdisease (SMR
= 72). The major finding is still the significantly el-
evated SMR for lymphosarcoma. The group with the
highest risk for this cause ofdeath appears to be those
employed fewerthan 10 years, first hired during World
War II, and employed in a job with the potential for
routine exposure. The fact that the risk does not in-
crease with increasing length ofemployment (and pre-
sumably increasing cumulative exposure) must be in-
corporated into anytheory that this excess is related to
1,3-butadiene exposure.
Although the leukemia SMR is not elevated for the
cohort overall, it is nonsignificantly elevated for the
nonroutine exposure group. Halfofthe leukemiadeaths
in this group occurred in persons who were first em-
ployed during the war and employed less than 5 years.
Overall, six ofthe eighttotalleukemiadeaths were first
employed during the war. Again, the risk does not
increase with length ofemployment. The increased risk
123124 n*B. J. DIVINE
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Table 4. Observed and expected deaths and standardized mortality ratios for selected causes for
Exposure group I: Exposuregroup I: Exposure group II:
lowexposure low exposure routine exposure
everemployed employed >10 years everemployed
n=433, P-Y = 11852 n = 190, P-Y = 3995 n=705, P-Y = 21422
Observed Expt 95% Observed Expeted 95% Observed Expected 95%
Causeofdeath(8th ICDAa) deaths deaths SMR' CIa deaths deaths SMR CI deaths deaths SMR CI
AJIcauses 131 163.1 80 67-95 58 83.3 70 53-90 163 213.1 76 65-89
Allcancers (140-209) 24 33.9 71 41-105 7 17.6 40 16-82 42 46.3 91 65-123
Cancerofbuccal cavityandpharynx (140-149) 0 1.0 0 0-361 0 0.5 0 0-717 1 1.4 70 1-389
Cancerofdigestive system(150-159) 9 9.4 96 44-183 2 4.9 41 5-148 9 12.0 75 34-142
Cancerofesophagus (150) 2 0.8 253 28-915 0 0.4 0 0-899 0 1.1 0 0-335
Cancerofstomach(151) 0 1.7 0 0-221 0 0.8 0 0-439 1 2.0 50 1-279
Canceroflargeintestine (153) 4 3.1 127 34-326 2 1.7 119 13-430 4 4.1 99 27-253
Cancerofrectum(154) 0 1.0 0 0-366 0 0.5 0 0-706 1 1.2 81 1-452
Cancerofliver(155-156) 1 0.7 143 2-796 0 0.4 0 0-1022 0 0.9 0 0-413
Cancerofpancreas (157) 2 1.8 110 12-397 0 1.0 0 0-382 2 2.4 82 9-297
Cancerofrespiratory system(160-163) 7 11.7 60 24-123 3 6.1 49 10-143 14 17.0 83 45-138
Cancerofthelarynx(161) 0 0.5 0 0-747 0 0.3 0 0-1454 2 0.7 296 33-1070
Canceroflung(162-163) 6 11.1 63 25-129 3 5.8 52 10-151 12 16.1 74 38-130
Cancerofbone(170) 0 0.1 0 0-2569 0 0.1 0 0-5740 1 0.2 516 7-2870
Cancerofskin (172-173) 2 0.6 351 39-1268 0 0.3 0 0-1354 0 0.9 0 0-413
Cancerofprostate (185) 0 2.5 0 0-147 0 1.5 0 0-246 2 2.6 77 9-277
Cancerofbladder(188) 0 1.1 0 0-351 0 0.6 0 0-623 1 1.2 84 1-467
Cancerofkidney(189) 2 0.8 241 27-871 1 0.4 237 3-1321 2 1.2 169 19-610
Cancerofbrainand central nervous system(191-192) 0 0.9 0 0-391 0 0.4 0 0-877 0 1.5 0 1-242
Lymphaticandhematopoietic cancer(200-209) 4 3.2 126 34-323 1 1.6 63 1-352 8 4.5 177 76-349
Lymphosarcomaandreticulosarcoma (200) 2 0.6 321 36-1159 1 0.3 322 4-1791 5 0.9 561 181-1310
Hodgkin'sdisease (201) 1 0.3 294 4-1635 0 0.1 0 0-2843 1 0.6 179 2-998
Leukemiaandaleukemia (204-207) 1 1.3 76 1-424 0 0.7 0 0-556 1 1.8 56 1-311
Otherlymphatictissue (202, 203, 208) 0 0.9 0 0-422 0 0.5 0 0-790 1 1.2 80 1-448
Benignneoplasms (210-239) 0 0.5 0 0-820 0 0.2 0 0-1775 0 0.7 0 0-566
Diabetes mellitus (250) 0 2.3 0 0-159 0 1.2 0 0-305 1 3.0 34 0-188
Arterioscleroticheart disease (410-413) 43 58.1 74 54-100 23 31.2 74 47-111 48 72.5 66 49-88
Vascularlesions ofcentral nervous system (430-438) 14 10.9 128 70-215 9 6.2 145 66-276 6 11.4 52 19-114
Nonmalignantrespiratorydisease(460-519) 10 10.6 95 45-174 6 5.9 103 37-223 9 12.7 71 32-135
Pneumonia (480-486) 3 3.5 85 17-248 2 1.9 104 12-374 3 4.0 75 15-220
Emphysema (492) 2 2.4 85 10-306 2 1.4 146 16-526 2 2.7 74 8-267
Cirrhosisofliver(551) 0 3.7 0 0-98 0 1.7 0 0-215 2 6.1 33 4-119
Allexternal causes(800-998) 12 13.6 88 46-154 2 4.9 41 5-149 14 22.9 61 33-102
a8th ICDA, 8th International Classification ofDiseases; SMR, standardized mortality ratio; 95%CI, 95% confidence interval.
forthe category symptoms, senility, and ill-defined con-
ditions is not readily explainable. The increase is con-
centrated in persons who were employed fewer than 20
years, werefirstemployed duringthe war, and were not
in the low exposure group. Obviously this category
would decrease with more specific cause ofdeath infor-
mation from the attending physician.
Two other studieshave examined mortalityin cohorts
exposed to 1,3-butadiene although both cohorts con-
sisted ofpersonsengaged inthemanufacture ofstyrene-
butadiene rubber (SBR) and so had the opportunity for
multiple exposures. The first study by Matanoski and
Schwartz (3) covered males who had worked at eight
SBR manufacturing facilities in the U.S. and Canada.
The overall SMR (81) was very similar to that seen for
the current study. The only significant excess seen was
for arteriosclerotic heart disease among black males.
Risks were examined bymajor work areas as well as by
pay grade, and no significant differences in cancer mor-
tality for specific sites were seen. In particular, no
increase was seen for lymphosarcoma (SMR = 49) or
leukemia (SMR = 91).
The second study by Meinhardt et al. (4) covered
personsemployed atthe two SBRplantssuppliedbythe
facility in the currentstudy. The Meinhardtstudyfound
an elevated SMR for leukemiathat was concentrated in
people hired during the war. Elevated SMRs for lym-
phosarcoma were also seen although they were not
statistically significant and were not as high as those
seenin thisstudy. Onemajorproblemwithcomparisons
between the Meinhardt study and the current study is
the overlap between the study cohorts. There were 116
persons who were employed both at the 1,3-butadiene
and the SBR manufacturingfacilities, including at least
one of the leukemia deaths and one of the lymphosar-
comadeaths. Theincreasesforeachofthesepopulations
may be exaggerated because of this.
Another report among oil refinery workers also saw
an increase in a'number of causes of deaths for those
persons first employed during World War II (5). The
increase was seen for many of the specific cancer sites
including leukemia as well as for external causes of
death. This study and the Meinhardt study show the
elevation for leukemia but not for external causes of
death. There aretwopossibilitiesforthewartimediffer-
ences ifthey are real. One is that this group ofpeople is
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all cohort members by exposure group and length of employment.
Exposure group II: Exposuregroup III: Exposuregroup III:
routine exposure Nonroutine Nonroutine
employed > 10years everemployed employed >10 years
n = 270, P-Y = 6450 n = 993, P-Y = 27434 n = 419, P-Y = 8714
Exposuregroup IV:
Unknown
everemployed
n = 451, P-Y = 13513
Exposuregroup IV:
Unknown
employed >10years
n = 217, P-Y = 5008
Observed Expected 95% Observed Expected 95% Observed Expected 95% Observed Expected 95% Observed Expected 95%
deaths deaths SMR CI deaths deaths SMR CI deaths deaths SMR CI deaths deaths SMR CI deaths deaths SMR CI
61 85.1 72 55-92
15 19.5 77 43-127
0 0.6 0 0-604
5 5.1 99 32-231
0 0.5 0 0-777
0 0.8 0 0-457
4 1.7 233 63-596
0 0.5 0 0-727
0 0.4 0 0-997
1 1.0 96 1-535
4 7.4 54 15-138
0 0.3 0 0-1266
4 7.1 57 15-1415
0 0.1 0 0-335
0 0.4 0 0-1036
1 1.1 89 1-494
0 0.5 0 0-721
2 0.5 398 45-1436
0 0.6 0 0-615
1 1.8 56 1-310
0 0.4 0 0-1017
0 0.2 0 0-2081
0 0.7 0 0-523
1 0.5 185 2-1031
0 0.2 0 0-1507
0 1.2 0 0-306
22 30.5 72 45-109
1 4.6 22 0-120
2 5.3 38 4-137
1 1.5 65 1-363
0 1.2 0 0-311
0 2.5 0 0-147
4 6.9 58 16-148
361 408.6 88 79-98
59 83.1 71 54-92
2 2.5 80 9-290
10 23.6 42 20-78
0 1.9 0 0-189
1 4.4 23 0-126
7 7.8 90 36-185
0 2.6 0 0-142
0 1.8 0 0-204
2 4.5 45 5-161
24 27.9 86 55-128
1 1.2 83 1-462
23 26.4 87 55-131
0 0.4 0 0-1010
1 1.4 73 1-408
5 6.5 77 25-180
1 2.7 37 0-208
1 2.0 50 1-276
1 2.2 45 1-253
11 7.8 141 70-253
2 1.6 126 14-454
1 0.8 122 2-677
6 3.2 185 68-403
2 2.1 97 11-350
2 1.1 182 20-656
4 5.8 69 19-176
101 145.9 69 56-84
36 28.9 124 87-172
20 26.6 75 46-116
10 9.2 109 52-200
3 5.9 51 10-150
4 8.8 46 12-117
27 32.0 84 56-123
154 189.6 81 69-95
30 39.9 75 51-107
1 1.2 87 1-483
4 11.2 36 10-91
0 0.9 0 0-396
0 1.9 0 0-187
3 3.8 79 16-230
0 1.2 0 0-304
0 0.8 0 0-438
1 2.2 46 1-255
10 13.7 73 35-135
0 0.6 0 0-644
10 12.9 77 37-142
0 0.2 0 0-2480
1 0.6 166 2-923
5 3.4 146 47-341
1 1.4 74 1-411
1 1.0 105 1-586
0 0.9 0 0-398
4 3.6 112 30-287
1 0.7 141 2-783
1 0.3 344 4-1915
1 1.5 67 1-371
1 1.0 97 1-539
0 0.5 0 0-790
2 2.8 73 8-263
41 71.3 58 41-78
12 14.3 84 43-146
12 13.3 90 47-157
8 4.5 180 77-354
1 3.2 31 0-175
1 3.8 27 0-148
10 10.7 94 45-172
171 194.9 88 75-102
38 39.4 97 68-133
2 1.2 167 19-603
11 11.3 98 49-175
1 0.9 108 1-599
2 2.2 93 10-336
3 3.7 82 16-238
2 1.2 161 18-580
0 0.9 0 0-427
3 2.1 141 28-413
12 13.2 91 47-159
1 0.6 174 2-965
11 12.5 88 44-158
0 0.2 0 0-2079
0 0.7 0 0-553
3 3.0 100 20-292
1 1.3 80 1-444
0 1.0 0 0-382
3 1.1 283 57-827
2 3.7 55 6-197
0 0.7 0 0-03
0 0.4 0 0-907
0 1.5 0 0-239
2 1.0 209 23-753
0 0.5 0 0-702
4 2.8 144 39-369
58 69.3 84 64-108
7 13.9 50 20-104
10 12.3 81 39-149
7 4.4 160 64-331
0 2.7 0 0-136
4 4.3 93 25-238
11 15.6 71 35-126
81 82.9 98 78-121
17 17.9 95 55-153
1 0.6 182 2-1015
4 4.9 81 22-208
0 0.4 0 0-855
0 0.9 0 0-427
1 1.6 61 1-40
2 0.5 381 43-1376
0 0.4 0 0-1005
1 1.0 103 1-571
7 6.4 110 44-227
0 0.3 0 0-1380
7 6.0 116 46-239
0 0.1 0 0-318
0 0.3 0 0-1231
2 1.3 159 18-574
1 0.5 186 2-1034
0 0.4 0 0-825
2 0.5 415 47-1497
0 1.6 0 0-225
0 0.3 0 0-1086
0 0.2 0 0-2394
0 0.7 0 0-554
0 0.5 0 0-794
0 0.2 0 0-1702
1 1.2 84 1-468
23 30.8 75 47-1212
5 5.6 90 29-209
7 5.3 132 53-271
4 1.7 232 62-594
0 1.3 0 0-285
3 2.0 148 30-433
4 5.7 70 19-179
somehow different from those hired at other times,
perhaps because they were not eligible for the draft
because ofhealth reasons. The other is that there were
major differences in exposure duringthe warthat led to
the increases.
Inexaminingworkhistoryrecordsforanearlierstudy
ofTexaco workers (6), it became obvious that a number
of experienced persons were lent to the 1,3-butadiene
plant during the war. In fact, 122 persons overlapped
between the two studies. It is very likely that similar
overlaps exist with cohorts from other petroleum and
chemical facilities in the area. Since most of the el-
evations ofinterest were concentrated primarily in per-
sonswith short-termemployment, thequestionremains
of where else these persons were employed and what
other exposures could have lasted substantially longer
than those at the butadiene facility.
As mentioned in the earlier report on this cohort (1),
there are several weaknesses in this study. Because of
unreliable race designations, conclusions based on race-
specificratescould notbegenerated. Forthisreason, all
comparisons were made using white male mortality
rates. Second, no work histories or industrial hygiene
data were available for the time period of the study.
Almosthalfofthe cohort worked fewerthan 5 years and
obviously spent considerable working time elsewhere
with the possibility for numerous other exposures. As
mentioned above, it is this portion ofthe cohort where
the increased SMRs are concentrated. Finally, the co-
hort size is small, and the numbers become even smaller
for the exposure group analyses.
However, the study does cover one of the largest
cohorts involved solely in the manufacture ofbutadiene.
Thecohorthasbeenfollowedfor43yearsandincludesall
those with 6months ormoreemploymentsincetheplant
began production. The numbers with vital status un-
known (1.9%) and without cause of death information
(6%) are relatively small, and qualitative measures of
exposures were available.
Furtherefforts areunderwaytoincreasetheinforma-
tion available for this cohort. Information has been re-
ceived from the NDI for those persons with vital status
unknown or for whom no death certificate could be
located based on SSA information. There are out-
standingrequests fordeathcertificatesfromother state
health departments, and additional death certificates
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Table 5. Observed and expected deaths by years worked and
latency for the total cohort.
Latency, years
Years worked 0-9 10-19 20-29 30+ Totals
Table 6. Observed and expected deaths by years worked and
latency for the low-exposure group.
Latency, years
Years worked 0-9 10-19 20-29 30+ Totals
All deaths
< 10
10-19
20+
Totals
Cancer deaths
< 10
10-19
20+
Totals
All hematopoietic
deaths
< 10
10-19
20+
Totals
Lymphosarcoma
deaths
< 10
10-19
20+
Totals
Leukemia
< 10
10-19
20+
Totals
Observed 84 98 123 167 472
Expected 101.3 91.8 145.9 199.9 538.9
SMRa 8.3 107 84 84 88
Observed - 56 54 44 154
Expected - 89.0 52.6 40.6 182.2
SMR - 63 103 108 85
Observed - - 76 124 200
Expected - - 100 158 258.0
SMR - - 76 79 78
Observed 84 154 253 335 826
Expected 101.3 180.8 298.5 398.5 979.6
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
aSMR, standardized mortality ratio.
83 85 85 84 84
11 19 26 38 94
13.8 16.2 30.2 47.6 107.8
80 117 86 80 87
7 9 6 22
16.2 9.8 7.4 33.4
43 92 81 66
20 27 47
22.1 39.3 61.4
91 69 77
11 26 55 71 163
13.8 32.4 62.1 94.3 202.7
80 80 89 75 80
4 3 4 8 19
2.0 1.9 2.8 3.9 10.6
200 158 143 205 179
0 3 0 3
1.8 0.9 0.6 3.3
0 333 0 91
- - 2 1 3
- 2.0 3.2 5.2
100 31 58
4 3 9 9 25
2.0 3.7 5.7 7.7 19.2
200 81 158 117 130
4 0 1 2 7
0.3 0.5 0.7 0.6 2.1
1333 0 143 3333 3333
- 0 0 0 0
0.5 0.2 0.1 0.8
0 0 0 0
2 0 2
0.5 0.5 1.0
400 0 200
4 0 3 2 9
0.3 1.0 1.4 1.2 3.9
1333 0 214 167 229
0 1 2 4 7
0.9 0.8 1.1 1.6 4.4
0 125 182 250 159
0 1 0 1
- 0.7 0.4 0.3 1.4
0 2.5 0 71
0 0 0
0.8 1.3 2.1
0 0 0
0 1 3 4 8
0.9 1.5 2.3 3.2 7.9
0 67 130 125 102
All deaths
< 10
10-19
20+
Totals
Cancer deaths
< 10
10-19
20+
Totals
All hematopoietic
deaths
< 10
10-19
20+
Totals
Lymphosarcoma
deaths
< 10
10-19
20+
Totals
Leukemia
< 10
10-19
20+
Totals
Observed
Expected
SMRa
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
14 11 17 31 73
15.9 12.1 22.8 29.1 79.9
88 91 75 107 91
- 5 7 12 24
16.2 9.7 8.2 34.1
31 72 146 70
10 24 34
- 19.6 29.6 49.2
51 81 69
14 16 34 67 131
15.9 28.3 52.1 66.9 163.1
88 57 65 100 80
2 2 3 18 17
2.2 2.1 4.8 7.2 16.3
91 95 63 139 104
0 1 2 3
3.0 1.7 1.3 6.0
0 59 154 50
3 1 4
4.4 7.2 11.6
68 14 35
2 2 7 13 24
2.2 5.1 10.9 15.7 33.9
91 39 64 83 71
1
0.3
333
1
0.3
333
aSMR, standardized mortality ratio.
0 0 2 3
0.3 0.4 0.6 1.6
0 0 333 188
0 0 0 0
0.3 0.2 0.1 0.6
0 0 0 0
- 1 0 1
0.5 0.6 1.1
200 0 91
0 1 2 4
0.6 1.0 1.2 3.2
0 104 161 126
1 0 0 0 1
0.1 0.1 0.1 0.1 0.4
192 0 0 0 250
0 0 0 0
0.1 0.0 0.0 0.1
0 0 0 0
- - 1 0 1
0.1 0.1 0.2
1000 0 500
1 0 1 0 2
0.1 0.1 0.2 0.2 0.6
192 0 452 0 321
0 0 0 1 1
0.1 0.1 0.2 0.2 0.6
0 0 0 442 167
- 0 0 0 0
0.1 0.1 0.1 0.3
0 0 0 0
0 0 0
- - 0.2 0.3 0.5
0 0 0
0 0 0 1 1
0.1 0.2 0.4 0.5 1.43
0 0 0 188 76
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Table 7. Observed and expected deaths by years worked and
latency for the routine exposure group.
Latency, years
Years worked 0-9 10-19 20-29 30+ Totals
All deaths
< 10
10-19
20+
Totals
Cancer deaths
< 10
10-19
20+
Totals
All hematopoietic
deaths
< 10
10-19
20+
Totals
Lymphosarcoma
deaths
Observed
Expected
SMRa
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
14 20 26 42 102
18.1 18.9 35.0 56.0 128.0
77 106 74 75 80
6 2 3 11
13.7 3.0 3.8 20.5
44 67 79 54
- - 19 31 50
23.4 41.1 64.5
81 75 78
14 26 47 76 163
18.1 32.6 61.4 100.9 213.1
77 80 77 75 76
2 6
2.1 3.2
95 188
1
2.3
44
2 7
2.1 5.5
95 127
2 1
0.4 0.5
500 200
0
- 0.3
- 0
2 1
0.4 0.7
500 143
< 10 Observed 2 0
Expected 0.1 0.1
SMR 2000 0
10-19 Observed 0
Expected - 0.1
SMR 0
20+ Observed
Expected
SMR
Totals Observed 2 0
Expected 0.1 0.2
SMR 2000 0
Leukemia
< 10 Observed 0 0
Expected 0.2 0.2
SMR 0 0
10-19 Observed 0
Expected 0.1
SMR 0
20+ Observed
Expected
SMR -
Totals Observed 0 0
Expected 0.2 0.3
SMR 0 0
aSMR, standardized mortality ratio.
8 11 27
7.5 14.0 26.8
107 79 101
1 0 2
0.6 1.0 3.9
167 0 51
5 8 13
5.1 10.5 15.6
98 76 83
14 19 42
13.2 25.5 46.3
106 75 91
1 3 7
0.7 1.1 2.7
143 273 259
0 0 0
0.1 0.1 0.5
0 0 0
0 1 1
0.5 0.8 1.3
0 125 77
1 4 8
1.3 2.0 4.5
77 200 178.7
1 2 5
0.2 0.2 0.6
500 1000 833
o 0 0
0.0 0.0 0.1
0 0 0
0 0 0
0.1 0.1 0.2
0 0 0
1 2 5
0.3 0.3 0.9
333 667 561
0 1 1
0.3 0.5 1.2
0 200 83
0 0 0
0.0 0.0 0.1
0 0 0
0 0 0
0.2 0.3 0.5
0 0 0
0 1 1
0.5 0.8 1.8
0 125 56
Table 8. Observed and expected deaths by years worked for the
nonroutine exposure group.
Years worked
All deaths
< 10
10-19
20+
Totals
Cancer deaths
< 10
10-19
20+
Totals
All hematopoietic
deaths
< 10
10-19
20+
Totals
Lymphosarcoma
deaths
Latency, years
0-9 10-19 20-29 30+ Totals
Observed
Expected
SMRa
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
Observed
Expected
SMR
< 10 Observed 1
Expected 0.1
SMR 1000
10-19 Observed
Expected
SMR
20+ Observed
Expected
SMR
Totals Observed 1
Expected 0.1
SMR 1000
Leukemia
< 10 Observed 0
Expected 0.4
SMR 0
10-19 Observed
Expected
SMR
20+ Observed
Expected
SMR
Totals Observed 0
Expected 0.4
SMR 0
aSMR, standardized mortality ratio.
43 46 53 65 207
45.4 39.2 57.6 76.9 219.1
95 119 94 85 95
34 33 22 89
41.2 29.3 22.2 92.7
83 113 99 96
24 41 65
37.8 58.9 96.7
64 70 67
43 80 110 128 361
45.4 80.4 124.7 158.0 408.6
95 100 88 81 88
6 6 8 9 29
6.5 7.0 11.8 18.0 43.3
92 86 68 50 67
- 4 7 4 15
7.7 5.5 3.8 17.0
52 127 105 88
- 6 9 15
- - 8.4 14.3 22.7
71 63 66
6 10 21 22 59
6.5 14.7 25.7 36.1 83.1
92 68 82 61 71
1 1 2 3 7
0.8 0.8 1.1 1.5 4.2
125 125 182 200 167
0 3 0 3
0.8 0.5 0.3 1.6
0 600 0 188
1 0 1
0.7 1.1 1.8
143 0 56
1 1 6 3 11
0.8 1.6 2.3 2.9 7.8
125 63 261 104 141
0
0.2
0
0
0.2
0
0
0.4
0
1
0.3
333
0
0.3
0
1
0.6
167
0
0.3
0
0
0.2
0
1
0.2
500
1
0.6
167
2
0.4
500
1
0.2
500
0
0.3
0
3
0.9
333
0 1
0.2 0.8
0 125
0 0
0.0 0.3
0 0
0 1
0.2 0.4
0 250
0 2
0.4 1.6
0 126
2 5
0.6 1.7
333 294
0 1
0.2 0.7
0 143
0 0
0.5 0.8
0 0
2 6
1.3 3.2
154 185
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Table 9. Observed and expected deaths by years worked for the
unknown exposure group.
Latency, years
Years worked 0-9 10-19 20-29 30+ Totals
All deaths
< 10 Observed 13 21 27 29 90
Expected 22.0 21.7 30.6 37.8 112.1
SMRa 59 97 88 77 80
10-19 Observed 11 12 7 30
Expected 18.1 10.7 6.4 35.2
SMR 61 112 109 85
20+ Observed 23 28 51
Expected 19.2 28.5 47.7
SMR 120 98 110
Totals Observed 13 32 62 64 171
Expected 22.0 39.8 60.5 72.7 194.9
SMR 59 80 103 88 88
Cancer deaths
< 10 Observed 1 5 7 8 21
Expected 3.2 3.9 5.8 8.4 21.3
SMR 31 128 121 95 94
10-19 Observed - 2 0 0 2
Expected 3.2 1.9 1.2 6.3
SMR 63 0 0 32
20+ Observed 6 9 15
Expected 4.1 7.3 11.4
SMR 146 123 132
Totals Observed 1 7 13 17 38
Expected 3.2 7.1 11.8 16.9 39.4
SMR 31 99 110 101 97
All hematopoietic
deaths
< 10 Observed 0 1 1 0 2
Expected 0.4 0.4 0.6 0.7 2.1
SMR 0 250 167 0 95
10-19 Observed 0 0 0 0
Expected 0.4 0.2 0.1 0.7
SMR 0 0 0 0
20+ Observed 0 0 0
Expected 0.4 0.6 1.0
SMR - 0 0 0
Totals Observed 0 1 1 0 2
Expected 0.4 0.8 1.2 1.4 3.7
SMR 0 125 83 0 55
Lymphosarcoma
deaths
< 10 Observed 0 0 0 0 0
Expected 0.1 0.1 0.1 0.1 0.4
SMR 0 0 0 0 0
10-19 Observed - 0 0 0 0
Expected 0.1 0.0 0.0 0.1
SMR 0 0 0 0
20+ Observed 0 0 0
Expected 0.1 0.1 0.2
SMR 0 0 0
Totals Observed 0 0 0 0 0
Expected 0.1 0.2 0.2 0.2 0.7
SMR 0 0 0 0 0
Leukemia
< 10 Observed 0 0 0 0 0
Expected 0.2 0.2 0.2 0.3 0.9
SMR 0 0 0 0 0
10-19 Observed 0 0 0 0
Expected 0.2 0.1 0.1 0.4
SMR 0 0 0 0
20+ Observed 0 0 0
Expected 0.2 0.2 0.4
SMR 0 0 0
Totals Observed 0 0 0 0 0
Expected 0.2 0.4 0.5 0.6 1.5
SMR 0 0 0 0 0
aSMR, standardized mortality ratio.
have been requested based on the NDI search results.
The analyses will be repeated when these data are
available. In addition, the company intends to continue
to update cause of death information on the cohort at
periodic intervals.
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